Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Lassmann is active.

Publication


Featured researches published by M. Lassmann.


Thyroid | 2001

The Use of Three-Dimensional Ultrasound for Thyroid Volumetry

S. Schlögl; E. Werner; M. Lassmann; J. Terekhova; S. Muffert; S. Seybold; Chr. Reiners

Conventional two-dimensional (2-D) ultrasound is the standard method for the investigation of thyroid morphology. Volume calculations need model assumptions and are observer dependent. The present study performed with a commercially available three-dimensional (3-D) system Freescan added to a conventional ultrasound scanner compares the accuracy of conventional thyroid volumetry to several methods of 3-D volume determination. In vitro measurements were performed on thyroid phantoms with known volumes. The standard deviation of the normalized differences was 8.0% (3-D segmentation) and 10.5% (conventional). For the accuracy of volume determination in human thyroids we performed a postmortem study. The thyroid volume was calculated conventionally by the ellipsoid model and by two 3-D methods (segmentation and the newly developed multiplanar volume approximation). The reference volume was determined after resection by submersion. The standard deviation of the normalized differences was 26.9% for the conventional method, 9.7% for 3-D segmentation and 11.5% for the multiplanar volume approximation, showing significant better results for both 3-D methods and no significant difference between the 3-D methods. The 3-D system, therefore, achieves a better accuracy for thyroid volumetry than the conventional volumetry using planar images. In addition, the 3-D images are stored electronically and can be used for follow-up studies.


Journal of Endocrinological Investigation | 2000

The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production

Markus Luster; W. Reinhardt; C. Körber; M. Lassmann; H. Haenscheid; U. Michalowski; J. Rendl; E. G. Eising; K. Mann; Chr. Reiners

We present a case of a patient suffering from metastatic differentiated thyroid carcinoma (DTC) and insufficient endogenous TSH production suspicious of secondary hypothyroidism. The use of recombinant human TSH (rhTSH) enabled us to administer a therapeutic activity of radioactive iodine (RAI) under maximal TSH-stimulation, achieving a marked decrease in thyroglobulin accompanied by a clinical improvement.


Nuklearmedizin-nuclear Medicine | 2010

131I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies

Frederik A. Verburg; Markus Luster; M. Lassmann; Christoph Reiners

UNLABELLED Due to its excellent tolerability and low incidence of side effects, 131I therapy has been the treatment of choice for benign thyroid diseases for over 60 years. A potentially increased risk of malignancies due to this therapy is however still subject of debate. AIM To review the literature pertaining to 131I therapy of benign thyroid diseases in order to establish whether there is an increased incidence of, or increased mortality due to malignancies of the thyroid or other organs. METHODS In order to allow for sufficient long-term follow-up time after 131I therapy, only literature after 1990 was reviewed. Two criteria were applied to consider an increased incidence of malignancies linked to 131I therapy: a) there should be a latency period of at least 5 years between 131I therapy and the observation of an increased risk b) an elevated risk should increase with increasing radiation exposure. RESULTS A total of 7 studies reporting cancer incidence and / or mortality in 4 different patient collectives spanning a total of 54510 patients over an observation period varying from 2-49 years were found. Although some studies detected a slightly increased risk for malignancies of the thyroid or the digestive system, others did not find these effects - while other studies even reported a slightly lower risk of malignant (thyroid) disease after 131I therapy for benign thyroid diseases. CONCLUSION As over 60 years of experience has thus far failed to produce conclusive evidence to the contrary, it can be concluded that there is no increased risk of malignancies after 131I therapy for benign thyroid disease.


International Journal of Low Radiation | 2006

Risk analysis of thyroid cancer incidence after exposure in childhood in the most contaminated areas of Ukraine, Belarus, and Russia in comparison with other studies

G. Goulko; Mykola Tronko; Tetyana I. Bogdanova; K. Henrichs; I. Kayro; V. Shpak; M. Lassmann; Chr. Reiners

The current knowledge about thyroid cancer induction due to 131I exposures during childhood is limited. Due to the low incidences observed, it was assumed that 131I is less effective in cancer induction by a factor of 3, if compared to external exposures. An increase of the thyroid cancer incidence among children and adolescents from the south-eastern Belorussian, the northern Ukrainian, and the western Russian oblasts after the reactor accident in Chernobyl is reported. As a result of the further improvement of the dose estimation methods, the individual exposure doses based on the results of direct thyroid activity measurement were recalculated, and the geographical pattern of age-dependent thyroid doses was analysed. These resulted in the re-assessment of collective doses and of thyroid cancer risk.


Nuklearmedizin-nuclear Medicine | 2004

Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2

M. Dietlein; J. Dressler; W. Eschner; F. Grünwald; M. Lassmann; B. Leisner; Markus Luster; E. Moser; Chr. Reiners; H. Schicha; O. Schober; für die Deutsche Gesellschaft für Nuklearmedizin


Nuklearmedizin | 2007

Intra- und Interobserver- Variabilität bei Schilddrüsenvolumenmessungen an gesunden Erwachsenen mittels 2Dim Vergleich zu 3D-Ultraschall

P. Andermann; S. Schlögl; U. Mäder; Markus Luster; M. Lassmann; Chr. Reiners


Nuklearmedizin-nuclear Medicine | 2007

Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound.

P. Andermann; S. Schlögl; U. Mäder; Markus Luster; M. Lassmann; Chr. Reiners


Journal of Endocrinological Investigation | 1999

Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131.

Chr. Reiners; Markus Luster; M. Lassmann


Thyroid | 2006

A Novel Thyroid Phantom for Ultrasound Volumetry: Determination of Intraobserver and Interobserver Variability

S. Schlögl; P. Andermann; Markus Luster; Chr. Reiners; M. Lassmann


Journal of Endocrinological Investigation | 2012

Recombinant human thyrotropin: safety and quality of life evaluation.

Chr. Reiners; M. Lassmann; Markus Luster

Collaboration


Dive into the M. Lassmann's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chr. Reiners

University of Würzburg

View shared research outputs
Top Co-Authors

Avatar

C. Körber

University of Würzburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Rendl

University of Würzburg

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge